➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANAGLIFLOZIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Canagliflozin

Subscribe to access the full database, or Get Started for $10
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00642278	An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2008-04-01	The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
NCT00650806	A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2008-05-01	The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
NCT00963768	A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2007-06-01	The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (ie, blood levels of JNJ-28431754) and pharmacodynamics (ie, urine and blood levels of glucose) of JNJ-28431754 compared to placebo in patients with Type 2 diabetes mellitus.
NCT00968812	CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride	Completed	Janssen Research & Development, LLC	Phase 3	2009-09-01	The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Canagliflozin

Condition Name

Chart
Table

Condition Name for Canagliflozin
Intervention	Trials
Healthy	40
Diabetes Mellitus, Type 2	36
Type 2 Diabetes Mellitus	12
Type 2 Diabetes	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Canagliflozin
Intervention	Trials
Diabetes Mellitus	58
Diabetes Mellitus, Type 2	56
Kidney Diseases	6
Diabetic Nephropathies	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Canagliflozin

Trials by Country

Map
Table

Trials by Country for Canagliflozin
Location	Trials
United States	511
Canada	61
India	17
Mexico	17
Germany	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Canagliflozin
Location	Trials
Florida	28
California	27
Arizona	24
Texas	24
Ohio	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Canagliflozin

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Canagliflozin
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	20
Phase 2	10
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Canagliflozin
Clinical Trial Phase	Trials
Completed	73
Recruiting	22
Not yet recruiting	18
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Canagliflozin

Sponsor Name

Chart
Table

Sponsor Name for Canagliflozin
Sponsor	Trials
Janssen Research & Development, LLC	41
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	31
Janssen Scientific Affairs, LLC	8
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Canagliflozin
Sponsor	Trials
Industry	99
Other	45
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow

Mallinckrodt

Harvard Business School

Express Scripts

Boehringer Ingelheim

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.